What is semaglutide?
Semaglutide copies GLP-1, the fullness hormone your gut releases after eating — slowing digestion, quieting appetite, and steadying blood sugar. It's one of the most-studied molecules in modern metabolic medicine.
These articles cover it from every angle: mechanism, dosing, side effects, results measured in trials, and how compounded semaglutide differs from brand-name versions. It's prescription-only through Promise: a licensed provider reviews every request, and not everyone qualifies. If you're starting from zero, begin with the mechanism article — the rest makes more sense once the hormone story is clear.
188 articles on this topic
-
When Was Rybelsus Approved? September 20, 2019
Rybelsus was approved on September 20, 2019. The FDA letter marked the moment a GLP-1 medicine moved from injection-only treatment into a daily tablet.
-
Does Semaglutide Cause Cancer? What Studies Show
Human studies have not established that semaglutide causes cancer. The thyroid warning remains, and lower cancer rates in some studies are not proof of prevention.
-
STEP 1 Trial Results: What the 14.9% Average Means
The 68-week semaglutide study found 14.9% average weight loss versus 2.4% with placebo. The details show who was studied, who stopped treatment and what happened later.
-
Tirzepatide and Kidney Disease: Risks and Evidence
Kidney disease does not automatically rule out tirzepatide. The key questions are dehydration risk, recent kidney tests and what the newer studies actually measured.
-
TrumpRx GLP-1 Prices: Beyond the Starting Price
Wegovy pills start at $149 and some pen offers at $199. Later fills, strength and eligibility determine the bill that follows.
-
503B Outsourcing Facility: What the Term Means
A 503B facility can prepare compounded medicines for clinic stock under federal manufacturing rules. Its registration describes the facility, not a review of each medicine.
-
15 Percent Weight Loss: What the Numbers Show
At 220 pounds, 15 percent is 33 pounds. Trials also measured waist, blood pressure, blood sugar, sleep, pain and physical function—but those group averages are not a personal forecast.
-
Who Discovered GLP-1? The Team Behind the Medicine
No single scientist discovered GLP-1. The answer is a chain of teams that found the gene, identified the working hormone, tested what it did, and designed medicines that lasted long enough to use.
-
FDA Tentative Approval: What It Means
FDA tentative approval means an application has cleared the scientific review needed for approval, but a legal barrier still prevents U.S. marketing. It is a real milestone, not permission to sell the drug.
-
Does Medicare Cover GLP-1 for Weight Loss? It Can
Some Medicare patients now qualify for a $50 monthly GLP-1 prescription. The Bridge has specific product and health requirements, and compounded prescriptions are outside it.
-
Semaglutide Meal Plan: A Simple Day Structure
A useful plan is flexible: smaller meals, protein early, fiber at a tolerable pace, and fluids across the day. This sample day uses portion ranges rather than a calorie rule.
-
Compounded Semaglutide Side Effects: What Changes?
Most compounded semaglutide side effects come from semaglutide itself. Compounding can add separate risks involving concentration, added ingredients, ingredient form, sterility, and labeling.
-
Semaglutide Pronunciation: How to Say It
Semaglutide is pronounced sem-a-GLOO-tide. The middle is easier once you know where the stress goes and why several related medicine names share the same ending.
-
503B Bulks List GLP-1: Still a Proposal
FDA proposes leaving three GLP-1 ingredients off the 503B bulks list. Comments closed July 30; patient-specific prescriptions follow separate rules.
-
Semaglutide Type 1 Diabetes: Guidance Has Limits
New 2026 guidance treats GLP-1 therapy as a possible obesity tool for some adults with type 1 diabetes, not as a replacement for insulin. The evidence is promising but small, and semaglutide is not approved to treat type 1 diabetes.
-
Novo Nordisk Lilly Lawsuit: What It Doesn't Decide
The fight is about how Zepbound ads frame a head-to-head trial after a higher Wegovy dose reached the market. It is not a court verdict on which medication is better for you.
-
Semaglutide News Update: September 2026
New child-trial results, heart-failure guidance, access changes and a June label update—what each means for a semaglutide prescription.
-
Semaglutide Before and After: An Honest Timeline
The first month is usually an adjustment period, month six is still part of the active curve, and a plateau often comes much later. Photos cannot show the treatment, timing, or follow-up behind a change.
-
FDA Telehealth Compounded Drugs: 5 Red Flags
FDA says telehealth sites must not present a compounded drug as a generic, a brand equivalent, or an agency-reviewed product. Here is what an honest prescription page should make clear.
-
Generic Semaglutide Exists—Just Not in the U.S.
Canada now has authorized semaglutide generics. The U.S. has only a tentative approval, while compounded semaglutide is another category altogether.
Page 6 of 10 · 188 articles